Amp Volatility Score
Catalyst Info & Data Links
NCT02649790: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/Refractory Cancer Indications
Zhang, J., Chism, D. D., Tagawa, S. T., Monk, P., Alter, R. S., Reichman, W., ... & Kauffman, M. G. (2019, March). Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic castration-resistant prostate cancer (mCRPC). In Journal of Clinical Oncology (Vol. 37, No. 7). 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA: AMER SOC CLINICAL ONCOLOGY.
Argueta, C., Kashyap, T., Chang, H., Klebanov, B., Friedlander, S., Baloglu, E., ... & Senapedis, W. (2017, July). Disruption of nuclear export with selinexor or KPT-8602 reduces androgen receptor expression and leads to potent anti-tumor activity in preclinical models of androgen-independent prostate cancer. In Cancer Research (Vol. 77). 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA: AMER ASSOC CANCER RESEARCH.
Maity, S. N., Wu, G., Lu, J. F., Hoang, A., Landesman, Y., McCauley, D., ... & Araujo, J. C. (2014). Preclinical efficacy of the novel, oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330) on castration resistant prostate cancer.
From 2019 10K:"We began clinical testing of eltanexor, a second-generation SINE compound, in late 2015. Our clinical development program for eltanexor includes myelodysplastic syndrome, or MDS, colorectal cancer, or CRC, and metastatic castration-resistant prostate cancer, or CRPC. Based on clinical results to date and resource prioritization, we plan to focus on the development of eltanexor in MDS in 2020."
HC updated 5/22/20